Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1

J Invest Dermatol. 2016 Jun;136(6):1172-1181. doi: 10.1016/j.jid.2016.01.033. Epub 2016 Feb 16.


Delivery of vaccine formulations into the dermis using antigen-coated microneedle patches is a promising and safe approach because of efficient antigen delivery and safety. We evaluated an intradermal vaccine using HIV-1 p24 Gag peptide-conjugated polypropylene sulfide nanoparticles to induce immunity against HIV-1. This peptide-conjugated polypropylene sulfide nanoparticle formulation did not accelerate the maturation of blood- or skin-derived subsets of dendritic cells, either generated in vitro or purified ex vivo, despite efficient uptake in the absence of adjuvant. Moreover, dendritic cell-mediated capture of particulate antigen in this form induced potent HIV-1-specific CD4(+) T-cell responses, as well as B-cell-mediated antibody production. Nanoparticle-based intradermal antigen delivery may therefore provide a new option in the global effort to develop an effective vaccine against HIV-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology*
  • Cells, Cultured
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Drug Delivery Systems / methods*
  • HIV Infections / prevention & control
  • HIV-1 / drug effects
  • HIV-1 / immunology*
  • Humans
  • Immunity, Cellular / drug effects*
  • Nanoparticles / administration & dosage
  • Polypropylenes / pharmacology
  • Sulfides / pharmacology
  • Vaccines / administration & dosage*


  • Polypropylenes
  • Sulfides
  • Vaccines